New drug duo shows promise for tough leukemia cases
NCT ID NCT04666649
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 29 times
Summary
This early-phase study tested a combination of two drugs, pegcrisantaspase and venetoclax, in 27 adults whose acute myeloid leukemia had returned or not responded to prior treatments. The main goal was to check safety and find the best dose. Researchers also looked at how many patients achieved complete remission. This approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.